All In Biotech

Drug Trial Radar · NCT05965167

Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo

A Phase 1b, Open-label, Partially Randomised Study to Assess Safety and Compare Pharmacokinetics of New Oral hPTH(1-34) Tablet Formulations vs. Oral EBP05 Tablets and Subcutaneous Forteo® Injection in Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

May 11, 2023

Primary completion

Feb 8, 2026

Study completion Feb 8, 2026

Sponsor

Lead sponsor
Entera Bio Ltd.Industry
Sponsor type
Industry
First posted
Jul 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize and compare the pharmacokinetics of hPTH(1 34) after treatment with modified oral formulations (EBP11, EBP11-F1, EBP11-F2, EBP11-F4, EBP11-F5 and EBP22) versus three dose levels of Entera Bio's extensively studied oral EBP05 1.5 mg, 2.5 mg and 3.0 mg as well as the commercial Forteo 0.02 mg subcutaneous injection.

Conditions

  • Hypoparathyroidism
  • Osteoporosis
  • Fractures, Bone
  • Other Disease

Interventions

  • EBP05Drug

    Oral tablets

  • Forteo 0.02 mgDrug

    Subcutaneous injection

  • EBP11Drug

    Oral tablets

  • EBP22Drug

    Oral tablets

  • EBP11-F2Drug

    Oral tablets

  • EBP11-F4Drug

    Oral tablets

  • EBP11-F1Drug

    Oral tablets

  • EBP11-F5Drug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the pharmacokinetic profile of plasma hPTH(1-34) after single or twice daily oral administration for treatment regimen as listed under Arms and Interventions at 5, 10, 15, 20, 40, 50, 60, 75, 90, 105, 120, 180, 240, 360 min. post doseTime frame: 6 hours
  2. Calculation of plasma levels of hPTH(1-34) AUC0-t for each treatment regimenTime frame: 6 hours
  3. Calculation of plasma levels of hPTH(1-34) AUC0-inf for each treatment regimenTime frame: 6-14 hours
  4. Calculation of plasma levels of hPTH(1-34) AUC%extrap for each treatment regimenTime frame: 6-14 hours
  5. Calculation of plasma levels of hPTH(1-34) Cmax for each treatment regimenTime frame: 6-14 hours
  6. Calculation of plasma levels of hPTH(1-34) Tmax for each treatment regimenTime frame: 6-14 hours
  7. Calculation of plasma levels of hPTH(1-34) Kel for each treatment regimenTime frame: 6 hours
  8. Calculation of plasma levels of hPTH(1-34) t½ for each treatment regimenTime frame: 6-14 hours
  9. Calculation of plasma levels of hPTH(1-34) Tlast for each treatment regimenTime frame: 6-14 hours
  10. Assessment of inter-subject variability of hPTH(1-34) for each treatment regimenTime frame: 6-14 hours
  11. Calculation of dose proportionality for hPTH(1-34) for relevant treatment regimenTime frame: 6 hours
  12. Assessment of the duration of exposure to hPTH(1-34) in minutesTime frame: 6 hours
  13. Vital Signs - body temperature (Celsius)Time frame: 6 hours
  14. Vital Signs - respiratory rate (breaths per minute)Time frame: 6 hours
  15. Vital Signs - blood pressure (systolic/diastolic mmHg)Time frame: 6 hours
  16. Vital Signs - heart rate (beats per minute)Time frame: 6 hours
  17. Incidence of Treatment-Emergent Adverse Events as assessed by the Principle InvestigatorTime frame: 6-14 hours
  18. Incidence of Serious Adverse Events (SAEs) as assessed by the Principle InvestigatorTime frame: 6-14 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Center Hadassah Ein Kerem Medical Center

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.